Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995;39(Suppl 1):29S–33S. doi: 10.1111/j.1365-2125.1995.tb04499.x

Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers

G Apseloff, K D Wilner, N Gerber
PMCID: PMC1364933  PMID: 7547090

Abstract

1 An open-label, randomised study was performed to assess the effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin.

2 Fourteen healthy male volunteers received either a single oral dose of 120 mg tenidap sodium or matching placebo capsules from days 11 to 36. A single oral dose of 0.75 mg kg-1 warfarin was administered on days 1 and 32.

3 The mean prothrombin AUC(0, 120h) value between baseline and day 32 increased from 1692.4 ± 234.5 s h to 1769.3 ± 218.0 s h in the group given tenidap, and decreased from 1747.6 ± 289.4 s h to 1708.1 ± 236.8 s h in the placebo group.

4 Tenidap caused a slight delay in the normalisation of prothrombin times following the second dose of warfarin on day 32 compared with the first dose on day 1. This was significant at 36, 48, 72 and 96 h but not at 120 h after administration of warfarin.

5 The mean percentage of unbound warfarin in the tenidap group (0.08% ± 0.09) was significantly different (P = 0.047) from that in the placebo group (-0.03% ± 0.10) but this was not considered to be clinically meaningful.

6 These data indicate that prothrombin times should be monitored during concomitant administration of tenidap and warfarin.

Keywords: tenidap sodium, warfarin, pharmacodynamics, plasma protein binding

Full text

PDF
29S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers G. W., Atwood J. E., Hirsh J., Sherman D. G., Hughes R. A., Connolly S. J. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med. 1991 Nov 1;115(9):727–736. doi: 10.7326/0003-4819-115-9-727. [DOI] [PubMed] [Google Scholar]
  2. Brater D. C. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med. 1986 Jan 17;80(1A):62–77. doi: 10.1016/0002-9343(86)90933-2. [DOI] [PubMed] [Google Scholar]
  3. Day R. O., Graham G. G., Champion G. D., Lee E. Anti-rheumatic drug interactions. Clin Rheum Dis. 1984 Aug;10(2):251–275. [PubMed] [Google Scholar]
  4. Furst D. E. Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications. J Rheumatol Suppl. 1988 Oct;17:58–62. [PubMed] [Google Scholar]
  5. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Longenecker G. L., Swift I. A., Bowen R. J., Beyers B. J., Shah A. K. Kinetics of ibuprofen effect on platelet and endothelial prostanoid release. Clin Pharmacol Ther. 1985 Mar;37(3):343–348. doi: 10.1038/clpt.1985.50. [DOI] [PubMed] [Google Scholar]
  7. Marbet G. A., Duckert F., Walter M., Six P., Airenne H. Interaction study between phenprocoumon and flurbiprofen. Curr Med Res Opin. 1977;5(1):26–31. doi: 10.1185/03007997709108972. [DOI] [PubMed] [Google Scholar]
  8. McIntyre B. A., Philp R. B., Inwood M. J. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther. 1978 Nov;24(5):616–621. doi: 10.1002/cpt1978245616. [DOI] [PubMed] [Google Scholar]
  9. Mirsen T. R., Hachinski V. C. Transient ischemic attacks and stroke. CMAJ. 1988 Jun 15;138(12):1099–1105. [PMC free article] [PubMed] [Google Scholar]
  10. Schulman S., Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol. 1989 Feb;28(1):46–49. doi: 10.1093/rheumatology/28.1.46. [DOI] [PubMed] [Google Scholar]
  11. Sipe J. D., Bartle L. M., Loose L. D. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J Immunol. 1992 Jan 15;148(2):480–484. [PubMed] [Google Scholar]
  12. Slattery J. T., Levy G. Effect of ibuprofen on protein binding of warfarin in human serum. J Pharm Sci. 1977 Jul;66(7):1060–1060. doi: 10.1002/jps.2600660747. [DOI] [PubMed] [Google Scholar]
  13. Smith G. M., Ward R. L., McGuigan L., Rajkovic I. A., Scott K. F. Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheumatol. 1992 Mar;31(3):175–178. doi: 10.1093/rheumatology/31.3.175. [DOI] [PubMed] [Google Scholar]
  14. Verbeeck R. K. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet. 1990 Jul;19(1):44–66. doi: 10.2165/00003088-199019010-00004. [DOI] [PubMed] [Google Scholar]
  15. Wilner K. D., Gardner M. J. Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers. Br J Clin Pharmacol. 1995;39 (Suppl 1):39S–42S. doi: 10.1111/j.1365-2125.1995.tb04501.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES